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Abstract 
Background: 
   
Inguinal metastases in patients affected by anal cancer are an independent prognostic 
factor for local failure and overall mortality. Since 2001, sentinel lymph node biopsy was 
applied in these patients. This original study reports an update of personal and previous 
published series, which were compared with Literature to value the incidence of inguinal 
metastases T-stage related and the overall incidence of false negative inguinal metastases 
at sentinel node. 
 
 
Methods: 
   
In all, 63 patients diagnosed with anal cancer submitted to inguinal sentinel node. 
Furthermore a research in the Pub Med database was performed to find papers regarding 
this technique. 
Results: 
   
In our series, detection rate was 98.4%. Inguinal metastases were evidentiated in 13 
patients (20.6%). Our median follow-up was 35 months. In our series, no false negative 
nodes were observed. 
Conclusion: 
   
Sentinel node technique in the detection of inguinal metastases in patients affected by 
anal cancer should be considered as a standard of care. It is indicated for all T stages in 
order to select patients to be submitted to inguinal radiotherapy, avoiding related morbidity 
in negative ones. An overall 3.7% rate of false negative must be considered acceptable. 
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Anal cancer remains a rare disease. An estimated 5820 new cases (2140 men and 3680 
women) were estimated to occur in the United States in 2011, accounting for 
approximately 2.1% of digestive system cancers. It has been estimated that 770 deaths 
due to anal cancer will occur in United States alone in 2011 (Siegel et al, 2011). 
In recent years, fluorodeoxyglucose-positron emission tomography/computed tomography 
(18F-FDG-PET/CT) (Mistrangelo et al, 2012) and sentinel lymph node biopsy (SLNB) of 
inguinal nodes have been introduced in clinical practice. 
SLNB was proposed in 2000 by John Spratt, who suggested that prophylactic groin 
dissection is not required, but it may be curative in many cases for enlarged nodes or in 
the presence of a positive SLNB (Spratt, 2000). 
Since 2001, SLNB was applied in patients affected by anal cancer providing inguinal 
staging and permitting a better planning of radiotherapic planes, avoiding inguinal 
radiotherapy and related morbidity in patients without metastasis at SLNB (Keshtgar et al, 
2001). 
Up to now, several studies (Vajda et al, 2001; Mistrangelo et al, 2002; Peley et al, 2002; 
Rabbit et al, 2002; Bobin et al, 2003; Damin et al, 2003; Ulmer et al, 2003; Castro et al, 
2005; Gretschel et al, 2008; Mariani et al, 2008; Mistrangelo et al, 2009a; Hirche et al, 
2010; De Nardi et al, 2011) and two reviews (Damin et al, 2006; Mistrangelo et al
were published in international Literature. All reports agree that SLNB for staging inguinal 
nodes in anal cancer is easy, feasible and can help to detect occult inguinal metastatic 
disease, in order to select the patients to submit to inguinal radiotherapy. Gretschel et al 
(2008) precised that SLNB is mainly indicated in T1 and T2 tumours and it is not 
recommendable for larger (T3-T4) tumours, considering the high incidence of inguinal 
metastases (MTS), and in patients with previous surgical manipulation in the anal or 
inguinal region. 
Therefore, in 2010, De Jong et al (2010) reported a limited value of staging squamous cell 
carcinoma of the anal margin and canal using the sentinel node procedure in a prospective 
study with long-term follow up. The authors conclude that, because of the occurrence of 
inguinal lymph node MTS after a tumour-negative SLNB, the introduction of this procedure 
as a standard of care in all patients with anal carcinoma should be done with caution to 
avoid undertreatment of patients who otherwise would benefit from inguinal radiotherapy. 
Considering these late reports, we revised our series and those reported in Literature to 
value the incidence of inguinal MTS T-stage related and the incidence of false negative 
(FN) SLNB in order to confirm or exclude indication to SLNB in all T stages for patients 
affected by anal cancer. 
Patients and methods 
The study population consisted of 63 patients with anal cancer submitted to SLNB. The 
study was approved by the local ethics committee. The presenting symptoms were 
bleeding on defecation, sometimes associated with anal pain or the sensation of an anal 
mass. 
Clinical workup comprised digital rectal examination, anoscopy, rigid proctoscopy, clinical 
exam of inguinal nodes, total colonoscopy, CT scan, rectal endosonography and PET-CT 
scan. HIV status and related CD4 count were valued in order to verify if there is a 
correlation with inguinal MTS. Patients with perianal cancer were excluded from the study. 
All patients except those with an important palpable inguinal lymphadenopathy were 
studied for inguinal MTS with SLNB technique. 
All patients were informed about the procedure and gave their written informed consent. 
The technique of SLNB was previously decribed (Mistrangelo et al, 2009a). 
The procedure started with the radioisotope injection. We performed it in a time ranging 
between 3 and 24 h before surgery. The injection of the radiopharmaceutical should be 
carried out in the Nuclear Medicine Department in order to adhere to universal radiation-
safety precautions. We used Nanocoll, which is characterised by particles with a diameter 
of 80 nm, which are perfect for an adequate migration. 
All patients studied in our Department were injected with 37 MBq of nanocoll-Tc-99 m 
dextran 500 in a total volume of 0.4 ml, divided in four insulin syringes with a total volume 
of 0.1 ml per syringe. The injection was performed at the four cardinal points around the 
neoplasm. 
The injection could be performed directly in the case of a neoplasm located perianally or at 
the anal margin, while in case of neoplasms located in the anal canal, we used a 
disposable anoscope to achieve a correct injection of the nanocolloid around the 
neoplasm. For the administration of the substance, we used a 22-G needle. 
The procedure did not require anaesthesia and it did not present complications. A little 
pain in the injection site lasting few minutes was usually reported by the patient. 
Planar lymphoscintigraphic images were generally performed 2–3 h after injection. Images 
were obtained using a GE Millennium gamma camera (GE Healthcare, Milwaukee, WI, 
USA). It presents a high-resolution collimator and a rectangular detector with 59 
photomultipliers and crystal thickness of 5/8 inch. Acquistion window was set at 140 KeV 
(±10%). The matrix of planar images was 256 × 256. The images were obtained in an 
anterior and posterior view. Sometimes we performed a lateral scintigraphic view as well. 
Lymphoscintigraphy obtained with colloid particles permits easy evaluation of the main 
lymphatic drainage, showing the first node in which the tracer is captured. Colloids have 
the advantage of delayed wash out allowing the surgical procedure the same day or the 
day following the injection. 
Imaging analysis was performed by two readers, who participated in all phases of the 
procedure. 
The same day of the injection or the following day patients were submitted to inguinal 
SLNB in the operating theatre. No difference in terms of signal detection or accuracy was 
noted between the two groups. The procedure started with the localisation of the sentinel 
node. It was carried out with the use of a manual portable gamma probe. We used a 
Scintiprobe MR 100, Politech, Carsoli, Italy. To read the signal, the probe was directed 
away from the anus in order to remove the signal originating from the site of injection. 
When the positive signal was found, a cutaneous mark was positioned in order to fix the 
point of surgical incision. Generally, the surgical procedure was done under local 
anaesthesia. Under signal guidance, the biopsy of sentinel lymph node/s was performed. 
We considered a signal to be positive only when node and background radioactivity signal 
ratio was equal or superior to 5 : 1. We measured the radioactivity of the resected node to 
confirm its positivity after removal. Then we evaluated the persistence of radioactivity in 
the inguinal area in order to locate further sentinel nodes. We performed the procedure 
bilaterally in case of lymphoscintigraphy or intraoperative signal positive for bilateral 
migration. Nodes were then submitted to microscopic evaluation: 5–10 microsections at 
representative levels of each sentinel lymph node were obtained by a step sectioning 
technique for nodes >5 mm. These sections were stained with hematoxylin and eosin. If 
the SLN was classified free of MTS after routine hematoxylin and eosin examination, 
immunohistochemistry was performed by means of an anti-pancytokeratin antibody 
(AE1/AE3) in order to identify micrometastases or isolated tumour cells. 
Then patients were stratified for T stage in order to determine the incidence of inguinal 
MTS for each stage. 
On completion of pre-treatment assessment, patients were submitted to combined 
radiochemotherapy (RCT) treatment (Mistrangelo et al, 2009a; Mistrangelo et al, 2010; 
Mistrangelo et al, 2012). Inguinal radiotherapy was administered only to patients with 
metastatic inguinal lyph nodes at SLNB. 
At 1 and 3 months after the completion of RCT, patients underwent rectal digital 
examination, anoscopy with biopsy and PET/CT. Then patients were submitted to a follow-
up consisting of a digital rectal examination, anoscopy, clinical exam of inguinal nodes and 
tumour marker assay (CEA and CA 19-9, that are not specific, and only recently sieric 
YKL-40) every 3 months for 3 years and every 6 months in the following 2 years. A CT 
scan of the thorax and abdomen was performed yearly for 5 years. 
After the first 5 years, patients were submitted to a rectal examination, anoscopy, clinical 
exam of inguinal nodes and tumour marker assay every year for further 5 years. A CT 
scan was performed 8 and 10 years after the end of RCT. 
This accurate follow-up was performed to state the results of RCT, the incidence of 
persistence/recurrence of the disease and the incidence of inguinal MTS. 
Moreover, the follow-up was oriented to value the incidence of FN in SLNB (patients with 
an histological negative SLNB, but developing inguinal MTS within the first 6 months of 
follow up). and to compare our results with ones published in Literature after a 
bibliographic research on Pub Med database. All papers, including case reports, are 
evaluated. 
Statistical analysis 
Data are presented as means (±s.d.) or median and range and rate with percentage for 
continuous and categorical variables, respectively. 
Results 
Between November 2001 and May 2011, 63 patients with anal cancer were studied at our 
Department. Tumour biopsy revealed 63 squamous cell carcinomas. Patient 
characteristics are reported in Table 1. 
Table 1. Patient characteristics 
 
Patient Characteristics No. of patients (%) 
Sex 63 
 Male 24 (38.1) 
 Female 39 (61.9) 
Race   
 White 63 (100) 
Age (years)   
 Median 59 
 Range 32–82 
 HIV-seropositive 15 (23.8) 
Localisation   
 Anal canal 43 (68.2) 
 Anal margin 20 (31.7) 
T   
 T1 7 (11.1) 
 T2 35 (55.5) 
 T3 17 (26.9) 
 T4 4 (6.3) 
 
Migration of Nanocoll was bilateral in 37 patients (59.7%) and unilateral in 25 patients 
(40.3%). 
Detection rate was 98.4% (62 out of 63 patients). Median number of excised lymph nodes 
was 4 (range 1–14). 
Histological exam evidentiated inguinal MTS in 13 patients (20.6%). In all, 2 (15.4% of 
inguinal metastatic patients) of these patients presented bilateral inguinal MTS. In 1 (7.7%) 
of metastatic cases, micrometastases were found. No cases of isolated tumour cells were 
evidentiated in our series. 
Regarding HIV+ status, only 1 patient presented MTS (6.7% of HIV+ patients). This patient 
had a CD 4+ count=163. Considering this aspect, only three patients had a CD 4+ count 
<200 (20%). 
Incidence of inguinal MTS in HIV−patients was 25% (12 out of 48). 
Patients with inguinal metastatic disease were stratified for T stage (Table 2). 
 
Table 2. Inguinal metastases stratified for T stage. Our experience and review 
of the Literature 
 
 
Author (year) Patients MTS T1 T2 T3 T4 
Vajda et al (2001) 2 0 n.v. n.v. n.v. n.v. 
Peley et al (2002) 8 2 n.v. n.v. n.v. n.v. 
Perera et al (2003) 12 2 0/2 (0%) 2/10 (20%) 0/0 0/0 
Bobin et al (2003) 33 7 0/3 (0%) 3/19 
(15.8%) 4/8 (50%) 0/2 (0%) 
Damin et al (2006) 22 2 n.v. n.v. n.v. n.v. 
Gretschel et al 
(2008) 
40 6/20 4/7 (57%) 0/10 (0%) 2/3 
(66.6%) 0/0 (0%) 
Mariani et al (2008) 25 0 n.v. n.v. n.v. n.v. 
De Nardi et al 
(2011) 
11 3 0/2 (0%) 1/4 (25%) 2/5 (40%) 0/0 (0%) 
Hirche et al (2010) 12 2 1/4 (25%) 0/5 (0%) 0/2 (0%) 1/1 
(100%) 
De Jong et al 
(2010) 
21 7 0/2 (0%) 6/15 (40%) 1/4 (25%) 0/0 (0%) 
Francois et al 
(2010) 
34 5 n.v. n.v. n.v. n.v. 
Mistrangelo et al 
(this paper) 
63 13 
1/7 
(14.3%) 
5/35 
(14.3%) 
6/17 
(35.3%) 1/4 (25%) 
Total valuables 192 
45/172 
(26.2%) 
6/27 
(22.2%) 
17/98 
(17.3%) 
15/39 
(38.5%) 
2/7 
(28.6%) 
 MTS=metastases; n.v.=not valuated. 
 
In 53 patients, PET-CT was performed and compared with SLNB in 41 patients 
(Mistrangelo et al, 2012). PET/CT was positive for inguinal MTS in 12 of 53 patients 
(22.6%) and negative in 41 of 53 patients (77.4%). Inguinal node staging was compared 
with the results of SLNB, which was performed in 41 patients. Comparison between SLNB 
and PET/CT findings showed that SLNB confirmed the presence of inguinal MTS in only 8 
cases, with 4 of 41 patients (9.7%) false positive and 2 of 41 patients (4.9%) FN. 
Median follow-up was 35 months (range 3–86 months). In the first 6 months of follow up, 
none FN inguinal MTS occurred in our series. During follow-up, none of the patients 
negative for inguinal MTS at SLNB deveoped metachronous MTS. 
Discussion 
Anal cancer remains a rare disease but its incidence is increasing (Siegel et al, 2011), 
mainly in association with human papillomaviruses infection. 
Since 1974, multimodality treatment as proposed by Nigro et al (1974), which combines 
radiation and chemotherapy, has become the standard of care, with surgery reserved for 
salvage treatment following local failure. 
The overall 5-year survival rate reaches 70% in the absence of inguinal MTS (Gerard et al, 
2001), which are an independent prognostic factor for local failure and overall mortality 
according to a multivariate analysis in a phase 3 EORTC trial (Bartelink et al, 1997). The 
average incidence rate of synchronous inguinal MTS is 13% (range 3–23%), but if 
metachronous inguinal MTS are taken into account, the overall rate of inguinal 
involvement is 24% (16–36%) (Gerard et al, 2001). Inguinal involvement is usually 
unilateral, with <5% bilateral either synchronous or metachronous extension (Gerard et al, 
2001). Gerard et al (2001) reported a severe prognosis for patients with clinically large 
inguinal lymph nodes (37% 5-year overall survival rate for patients with lymph nodes >2 cm 
in greatest dimension), for patients with anal margin involvement (22.7%), and for patients 
with T3-T4 lesions (39%). Otherwise, the presence of concomitant perirectal lymph nodes 
did not significantly affect the prognosis. 
Considering these aspects, the detection of inguinal lymph nodes is mandatory in the 
treatment of these patients and for their prognosis. 
An array of tools for assessing inguinal metastasis have been proposed: clinical 
examination, endosonography, CT and magnetic resonance imaging; however, they are 
unable to detect nodal involvement in all the cases. Furthermore, only histological study 
can confirm MTS in a enlarged node or a micrometastasis in a normal-sized node. Wade 
et al (1989) at the Roswell Park Cancer Institute using a ‘clearing technique’ found that 
44% of perianal, perirectal and pericolonic lymph node MTS were <5 mm in diameter, and 
therefore indetectable by usual diagnostic tools. 
Recently, the use of FDG PET has also gained an important place in this setting, even if its 
role has yet to be defined (Mistrangelo et al, 2010; Mistrangelo et al, 2012). To better 
diagnose inguinal MTS, in recent years, SLNB has proven to be a safe and an effective 
technique (Spratt, 2000; Keshtgar et al, 2001; Vajda et al, 2001; Mistrangelo et al, 2002; 
Peley et al, 2002; Rabbit et al, 2002; Bobin et al, 2003; Damin et al, 2003; Ulmer et al, 
2003; Castro et al, 2005; Damin et al, 2006; Gretschel et al, 2008; Mariani et al, 2008; 
Mistrangelo et al, 2009a; De Jong et al, 2010; Hirche et al, 2010; De Nardi et al, 2011). 
The present study confirms that SLNB is a simple and feasible technique with a high 
detection rate (98.4%), as reported in Literature (47–100%). Inguinal MTS are found in 
20.6% of cases (13 patients), comparable with Literature (range 9.1–33% in major 
published series). 
In their paper, Gretschel et al (2008) concluded that the SLNB can be used to select 
patients for inguinal irradiation appropriately, especially in T1 and T2 tumours. These 
patients receive either additional treatment or are spared from unnecessary radiation. In 
their opinion, SLNB technique is not recommendable for larger T3-T4 tumours and in 
patients with previous surgical manipulation in the anal or inguinal region. 
Published data up to date do not justify these conclusions. In fact, cumulative data 
evidentiated that almost 2 out of 3 of T3 and T4 patients are disease free from inguinal 
MTS at SLNB. Moreover, systematic irradiation of the groins has proved to demand a 
larger volume of radiotherapy, which increases toxicity especially when associated with 
chemotherapy: acute toxicity-related deaths occurred in 2–2.7% of cases (Bartelink et al, 
1997) and late toxicity related to primary treatment, such a small bowel injury, soft tissue 
injury and neurogenic bladder, was reported to be as high as 33%, with 15% of patients 
requiring major medical or surgical intervention (Myerson et al, 2001). Otherwise in a study 
on 223 patients treated with chemoradiation sparing inguinal fields, Papillon and 
Montbarbon (1987) found metachronous inguinal MTS in only 7.4% of cases over a follow-
up period of >3 years; and in a more recent study on 270 patients treated without elective 
inguinal irradiation, late inguinal MTS were diagnosed in 7.8% of patients (Gerard et al, 
2001). In light of these results, authors concluded that the vast majority of patients (92%) 
submitted to routine inguinal irradiation are actually being overtreated (Gerard et al, 2001). 
Following on these considerations, Sapienza et al (1992) suggested that the low incidence 
of metachronous MTS and the high morbidity after inguinal lymphadenectomy and 
radiotherapy do not advocate the choice of preventive treatment. 
When we stratify patients for T stage, inguinal MTS are observed in 14.3% of T1 and T2 
patients, 35.3% of T3 and 25% of T4 ones. Considering overall data published in Literature 
on SLNB, inguinal MTS are found in 26.2% of all patients (45 out of 172): 22.2% of T1; 
17.3% of T2; 38.5% of T3; and 28.6% of T4 patients. 
Our series suggest that inguinal SLNB is indicated for all patients affected by anal cancer 
(obviously in the absence of large palpable inguinal lymph nodes, which must be directly 
biopsied) in order to select patients to submit to inguinal radiotherapy and avoid 
unnecessary treatment and associated morbidity. Also patients previously submitted to 
surgical manipulation in the anal or inguinal region could be submitted to SLNB, even if the 
migration of the tracer could be altered by previous anal surgery and the detection of 
inguinal nodes could be difficult. In case of absence of inguinal migration of the tracer, 
patient must be treated following the personal standard inguinal approach. In our series, 
five patients were previously submitted to surgery for an anal mass that revealed a 
squamous cancer with margins involved. Inguinal SLNB was performed without problems. 
The second aim of the study was to value the incidence of FN lymph nodes after SLNB. 
De Jong et al (2010) suggested that inguinal SLNB has a limited value considering the 
incidence of FN after the procedure. Our series were compared with the published ones in 
order to value the global incidence of FN. The result of the review, including our 
experience, evidentiated that 6 out of 163 (3.7%) lymph nodes negative at 
immunochemistry after SLNB developed inguinal MTS after a medium follow up of 27.3 
months (range 5–50 months). FN lymph nodes developed in three T1N0 cancers, one 
T2N0 and one T3N0 (in the case of Mariani et al (2008), the stage was not specified). Data 
of the review are reported in Table 3. 
 
Table 3. Review of the Literature of SLNB with the count of false negative (FN) 
|  
Author 
(year) 
Patients Localisation 
Palpable 
nodes 
Detection 
rate 
Technique MTS 
FU 
(mo) 
FN 
Vajda et al 
(2001) 
2 Not specified 
Not 
specified 
100% Combined 0% Not 
specified 
Not 
specified 
Keshtgar 
et al 
(2001) 
1 Anal margin No 100% Combined 0% Not 
specified 
Not 
specified 
Peley et al 
(2002) 
8 Not specified 
Not 
specified 
100% Combined 25% 5–35 0/6 0% 
Perera et 
al (2003) 
12 
Anal canal or 
margin 
Not 
specified 
67% Combined 29% Not 
specified 
Not 
specified 
Bobin et al 
(2003) 
33 Not specified No 100% Combined 21% 18 0/26 0% 
Castro et 
al (2005) 
2 
Anal canal or 
margin 
No 100% Combined 0% Not 
specified 
Not 
specified 
Damin et 22 Not specified No 100% Combined 9.1% Not Not 
Author 
(year) 
Patients Localisation 
Palpable 
nodes 
Detection 
rate 
Technique MTS 
FU 
(mo) 
FN 
al (2006) specified specified 
Gretschel 
et al 
(2008) 
40 
Anal canal or 
margin 
Not 
specified 
90% 
(inguinal 
56%) 
Nanocoll 
30% on 
20 
patients 
inguinal 
SLNB 
27 
1/14 
7.1% 
Mariani et 
al (2008) 
25 Not specified 
Not 
specified 
100% Combined 0% 20 2/25 8% 
De Nardi et 
al (2011) 
11 Anal canal No 100% Combined 27.2% 16 0/8 0% 
Hirche et al 
(2010) 
12 
Anal canal or 
margin 
No 83.3% Combined 
and ICG 
20% 44 0/8 0% 
De Jong et 
al (2010) 
21 
Anal canal or 
margin 
No 100% Combined 33% 31 2/14 
14% 
Francois et 
al (2010) 
34 
Anal canal or 
margin 
Not 
specified 
47% Nanocis 31.2% 50 1/11 9% 
Mistrangelo 
et al (this 
paper) 
63 
Anal canal or 
margin 
14 98.4% Nanocoll 20.6% 44.1 0/50 0% 
 Abbreviations: FU=follow up; ICG=indocyanine green; MTS=metastases; 
SLNB=sentinel lymph node biopsy. 
 
Considering these data, a FN rate of 3.7% should be considered as acceptable for patients 
affected by anal cancer. 
Moreover, 4 out of 5 (80%) of FN were T1-T2 patients (in one case, T stage was not 
specified) confirming that SLNB is indicated in all T stage and not only in T1-T2 as 
suggested by Gretschel et al (2008), considering that long follow-up confirm that almost 2 
out of 3 of T3-T4 patients are N0 or N1. 
Conclusions 
Up-to-date SLNB technique in the detection of inguinal MTS in patients affected by anal 
cancer should be considered as a standard of care. It is indicated for all T stages in order 
to select patients to be submitted to inguinal radiotherapy, avoiding morbidity associated to 
this treatment in patients negative for inguinal MTS. 
Notes 
This work is published under the standard license to publish agreement. After 12 months 
the work will become freely available and the license terms will switch to a Creative 
Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. 
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